Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vincerx Pharma, Inc. (VINC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3200-0.1300 (-8.97%)
At close: 04:00PM EDT
1.3200 0.00 (0.00%)
After hours: 07:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4500
Open1.4700
Bid1.3200 x 4000
Ask1.3500 x 1000
Day's Range1.3100 - 1.5400
52 Week Range1.2600 - 18.4270
Volume2,400,596
Avg. Volume160,975
Market Cap27.748M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.6530
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

    Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma patients treated with VIP152 PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer throu

  • Benzinga

    Analysts Cuts Price Target On This Small Cap But Remain Bullish

    Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also implemented a 33% workforce reduction and other cost reduction measures due to "unprecedented market conditions." The analyst updated his model to reflect a narrower de

  • Benzinga

    Small Cap Biotech Vincerx Cuts Third Of Staff

    Cancer-focused biotech Vincerx Pharma Inc (NASDAQ: VINC) would lay off 33% of its staff to get its lead program through two Phase I studies. The move comes a little less than two years after Vincerx went public via a SPAC and its stock fell more than 80% in 2022. “Reducing our staff was not an easy decision,” CEO Ahmed Hamdy said. “It was the tremendous effort of our Vincerx colleagues that allowed us to execute efficiently, despite the extreme pressures of the pandemic.” Vincerx said it is prio

Advertisement
Advertisement